Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
16 results
  • Head and Neck Cancer, Melanoma, Lung Cancer, Bladder Cancer

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Sarcoma, Prostate Cancer, Pancreatic Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Colorectal Cancer

25-464          Phase I

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors

  • Breast Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Head and Neck Cancer, Bladder Cancer, Cervical Cancer, Esophageal Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Colorectal Cancer, Melanoma, Breast Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Cervical Cancer, Bladder Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Pancreatic Cancer, Lung Cancer, Endometrial Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer

25-783          Phase I

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

  • Melanoma, Uterine Cancer, Ovarian Cancer, Lung Cancer, Endometrial Cancer, Breast Cancer, Bladder Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Gastric (Stomach) Cancer, Pancreatic Cancer, Esophageal Cancer, Endometrial Cancer, Liver Cancer, Sarcoma, Bladder Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Endometrial Cancer, Liver Cancer, Breast Cancer, Bladder Cancer

24-666          Phase II

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

  • Esophageal Cancer, Colorectal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer

25-448          Phase II

A Phase 1/2 Study of GEN1286 in Patients with Advanced Solid Tumors

Showing 1 - 10 of 16 results